Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies. Results from the Phase 2a human challenge study found that the compound ...
BOSTON, MA, USA and SEONGNAM, South Korea I October 4, 2024 I TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on ...
Aligns with Eton’s Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions DEER PARK, IL, USA I October 03, 2024 I Eton Pharmaceuticals, ...
TEL AVIV, Israel and MADRID, Spain I October 03, 2024 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius ...
MILAN, Italy I October 04, 2024 I Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
— Series B led by Goldman Sachs Alternatives with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors — — Funding will advance second-generation ...
– MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio’s ABL103 in a Phase 1b/2 clinical trial SEONGNAM, South Korea I October 4, 2024 I ABL Bio (CEO Sang Hoon Lee), a company ...
HAYWARD, CA, USA I October 02, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback